August 26, 2014
The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer
British Journal of Cancer, volume 111, pages 837–842 (26 August 2014).
R. Exner, Z. Bago-Horvath, R. Bartsch, M. Mittlboeck, V.P. Retèl, F. Fitzal, M. Rudas, C. Singer, G. Pfeiler, M. Gnant, R. Jakesz, P. Dubsky
According to MammaPrint (MP), 76% were low risk. In over a third of patients, discordance between clinical and molecular risk was observed. Decision changes were recorded in half of these cases (18.6%) and resulted in two out of three patients not requiring chemotherapy. The use of MP was also found to be more cost-effective.